R1 Therapeutics

About R1 Therapeutics

R1 Therapeutics is a kidney-focused biotechnology company developing first-in-class therapies for kidney disease. Its lead asset, AP306, is a pan phosphate transporter inhibitor designed to lower phosphate in patients with chronic kidney disease, potentially reducing pill burden and improving quality of life. The company aims to address hyperphosphatemia across the spectrum of kidney disease, including non-dialysis, dialysis, and transplant settings, with a patient-centric approach and a mission to redefine renal care.